Artykuły udostępnione publicznie: - Neha ShresthaWięcej informacji
Niedostępne w żadnym miejscu: 13
Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin
M Lopes, N Shrestha, A Correia, MA Shahbazi, B Sarmento, J Hirvonen, ...
Journal of controlled release 232, 29-41, 2016
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal
Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers
N Shrestha, MA Shahbazi, F Araújo, H Zhang, EM Mäkilä, J Kauppila, ...
Biomaterials 35 (25), 7172-7179, 2014
Upoważnienia: Fundação para a Ciência e a Tecnologia, Portugal
Thiolation and cell‐penetrating peptide surface functionalization of porous silicon nanoparticles for oral delivery of insulin
N Shrestha, F Araújo, MA Shahbazi, E Mäkilä, MJ Gomes, ...
Advanced Functional Materials 26 (20), 3405-3416, 2016
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal …
Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system
N Shrestha, MA Shahbazi, F Araujo, E Mäkilä, J Raula, EI Kauppinen, ...
Biomaterials 68, 9-20, 2015
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal …
Safety and toxicity concerns of orally delivered nanoparticles as drug carriers
F Araújo, N Shrestha, PL Granja, J Hirvonen, HA Santos, B Sarmento
Expert opinion on drug metabolism & toxicology 11 (3), 381-393, 2015
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal
Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model
N Shrestha, F Araujo, MA Shahbazi, E Mäkilä, MJ Gomes, M Airavaara, ...
Journal of Controlled Release 232, 113-119, 2016
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal …
A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors
MA Shahbazi, N Shrestha, E Mäkilä, F Araújo, A Correia, T Ramos, ...
Nano Research 8, 1505-1521, 2015
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal
The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers
N Shrestha, O Bouttefeux, K Vanvarenberg, P Lundquist, J Cunarro, ...
Nanoscale, 2018
Upoważnienia: National Fund for Scientific Research, Belgium, European Commission
Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles
MA Shahbazi, PV Almeida, A Correia, B Herranz-Blanco, N Shrestha, ...
Journal of Controlled Release 249, 111-122, 2017
Upoważnienia: Academy of Finland
Gene-based therapy for Type 1 diabetes mellitus: viral and nonviral vectors
N Shrestha, F Araújo, B Sarmento, J Hirvonen, HA Santos
Diabetes Management 4 (4), 367, 2014
Upoważnienia: Fundação para a Ciência e a Tecnologia, Portugal
Controlled Shape and Nucleation Switching of Interfacially Polymerizable Nanoassemblies by Methyl Substitution
MA Shahbazi, E Makila, N Shrestha, J Salonen, J Hirvonen, HA Santos
Chemistry of Materials 27 (23), 8170-8178, 2015
Upoważnienia: Academy of Finland, European Commission
In vivo testing of orally delivered nanoparticles
N Shrestha, V Préat
Nanotechnology for oral drug delivery, 459-480, 2020
Upoważnienia: National Fund for Scientific Research, Belgium
Cell-based in vitro models for buccal permeability studies
S Pinto, N Shrestha, F Araújo, J Hirvonen, HA Santos, B Sarmento
Concepts and Models for Drug Permeability Studies, 45-65, 2024
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal
Dostępne w jakimś miejscu: 14
Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems
BJ Boyd, CAS Bergström, Z Vinarov, M Kuentz, J Brouwers, P Augustijns, ...
European Journal of Pharmaceutical Sciences 137, 104967, 2019
Upoważnienia: European Commission
The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium
F Araújo, N Shrestha, MA Shahbazi, P Fonte, EM Mäkilä, JJ Salonen, ...
Biomaterials 35 (33), 9199-9207, 2014
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal
Overcoming the intestinal barrier: a look into targeting approaches for improved oral drug delivery systems
Y Xu, N Shrestha, V Préat, A Beloqui
Journal of Controlled Release 322, 486-508, 2020
Upoważnienia: National Fund for Scientific Research, Belgium
An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers
Y Xu, N Shrestha, V Préat, A Beloqui
Advanced Drug Delivery Reviews 175, 113795, 2021
Upoważnienia: National Fund for Scientific Research, Belgium, European Commission
Microfluidic assembly of a multifunctional tailorable composite system designed for site specific combined oral delivery of peptide drugs
F Araujo, N Shrestha, MA Shahbazi, D Liu, B Herranz-Blanco, EM Makila, ...
ACS nano 9 (8), 8291-8302, 2015
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal …
Microfluidic assembly of multistage porous silicon–lipid vesicles for controlled drug release
B Herranz-Blanco, LR Arriaga, E Mäkilä, A Correia, N Shrestha, S Mirza, ...
Lab on a Chip 14 (6), 1083-1086, 2014
Upoważnienia: European Commission
In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
F Araujo, N Shrestha, MJ Gomes, B Herranz-Blanco, D Liu, JJ Hirvonen, ...
Nanoscale 8 (20), 10706-10713, 2016
Upoważnienia: Academy of Finland, Fundação para a Ciência e a Tecnologia, Portugal …
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy